2015 Nobel Prize in Physiology or Medicine

The Nobel Prize in Physiology or Medicine 2015 was awarded to William C. Campbell, Satoshi Ōmura and Youyou Tu.  

William Campbell and Satoshi Ōmura shared one-half of the prize for their discoveries of a new drug, Avermectin, that was highly effective against a spectrum of parasitic worm infections.  The derivatives of this compound are currently being used to eradicate and prevent the transmission of River Blindness and Lymphatic Filariasis.

Youyou Tu was awarded the other half of the Nobel Prize for her discovery of Artemisinin, a drug that has become a frontline treatment for malaria and has significantly reduced the mortality rates for patients suffering from this disease worldwide.

In celebration, NPG is making available a range of articles from its journal archives that feature these scientists’ remarkable achievements and highlight recent progress in these fields. 


Two semi-synthetic processes for the production of the antimalarial natural product artemisinin have been developed by applying the principles of green chemistry. Solvent manipulation allows catalyst recycling and reduction of waste, ultimately leading to a purification-free process with lower environmental and economic costs; a potential contribution to the world-wide fight against malaria.

Article | | Nature Chemistry

In this study, the authors present an analysis of the malaria burden in sub-Saharan Africa between 2000 and 2015, and quantify the effects of the interventions that have been implemented to combat the disease; they find that the prevalence of Plasmodium falciparum infection has been reduced by 50% since 2000 and the incidence of clinical disease by 40%, and that interventions have averted approximately 663 million clinical cases since 2000, with insecticide-treated bed nets being the largest contributor.

Article | | Nature

The description of a compound (DDD107498) with antimalarial activity against multiple life-cycle stages of Plasmodium falciparum and good pharmacokinetic and safety properties, with potential for single-dose treatment, chemoprotection and prevention of transmission.

Article | | Nature

Saccharomyces cerevisiae is engineered to produce high concentrations of artemisinic acid, a precursor of the artemisinin used in combination therapies for malaria treatment; an efficient and practical chemical process to convert artemisinic acid to artemisinin is also developed.

Letter | | Nature

Dominic Kwiatkowski and colleagues report a large multicenter genome-wide association study of Plasmodium falciparum resistance to artemisinin. They identify markers of a genetic background on which kelch13 mutations conferring artemisinin resistance are likely to emerge.

Article | | Nature Genetics

Artemisinins are key anti-malarial drugs, but artemisinin resistance has been increasing; this study identifies the molecular target of artemisinins as phosphatidylinositol-3-kinase and increase of the lipid product phosphatidylinositol-3-phosphate induces resistance in Plasmodium falciparum.

Letter | | Nature